

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previously submitted listings of claims:

- 1-29. **(Cancelled)**
30. **(Previously Presented)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising:
administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.
- 31-70. **(Cancelled)**
71. **(Previously Presented)** The method of claim 30, wherein the antibody is selected from the group consisting of a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimeric antibody.
- 72-75. **(Cancelled)**
76. **(Previously Presented)** The method of claim 30, wherein the host is a human.
- 77-84. **(Cancelled)**
85. **(Currently Amended)** A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that specifically binds to an epitope of the antigen, wherein said tumor-associated antigen is CA 125, and wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope ~~associated with~~ of the tumor-associated antigen.
86. **(Previously Presented)** The composition of claim 85, wherein the antibody is selected from the group consisting a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimeric antibody.

87. **(Previously Presented)** The composition of claim 85, wherein the antibody is a monoclonal antibody.
88. **(Currently Amended)** A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of CA 125 and a monoclonal antibody produced by the hybridoma having ATCC deposit number PTA-1883 or antigen binding fragment thereof that specifically binds to an epitope of CA 125, wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope of CA 125 ~~The composition of claim 87, wherein the monoclonal antibody is produced by the hybridoma having ATCC deposit number PTA-1883.~~
- 89-95. **(Cancelled)**
96. **(Previously Presented)** The composition of claim 85, wherein the host is a human.
- 97-98. **(Cancelled)**
99. **(Previously Presented)** The method of claim 30, wherein the complex is administered with an adjuvant.
100. **(Previously Presented)** The method of claim 30, wherein the antibody or antigen binding fragment thereof of the complex is formulated at a dose of from about 0.1 µg to about 2 mg per kilogram of body weight of the host.
- 101-102. **(Cancelled)**
103. **(Currently Amended)** The method of claim 30, wherein the [[soluble]] complex induces cytotoxic T cells reactive with the antigen.
104. **(Previously Presented)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex consisting essentially of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies and cytotoxic T cells reactive with the tumor-associated antigen.

105. **(Previously Presented)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex consisting essentially of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces cytotoxic T cells reactive with the tumor-associated antigen.
106. **(Currently Amended)** The method of claim 105, wherein the [[soluble]] complex further induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.
107. **(Previously Presented)** A method of treating an oncological disease comprising administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.
108. **(Previously Presented)** The method of claim 107, wherein the complex induces cytotoxic T cells reactive with the tumor-associated antigen.
109. **(Previously Presented)** A method of treating an oncological disease comprising administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces cytotoxic T cells reactive with the tumor-associated antigen.
110. **(Previously Presented)** The method of claim 107, wherein the complex induces host antibodies reactive with at least one other epitope of the antigen.
111. **(Previously Presented)** The method of claim 30, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of about 2 mg per host.
112. **(Previously Presented)** The method of claim 30, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of from about 0.1 μ g to about 200 μ g

per kilogram of body weight of the host.

113. **(Currently Amended)** The method of any of claims 30, 104, 105, 107, [[and]] 109, 118, and 119, wherein the antibody is a non-human antibody.
114. **(Currently Amended)** The composition of claim 85 or 117, wherein the antibody is a non-human antibody.
- 115-116. **(Cancelled)**
117. **(Currently Amended)** A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that specifically binds to an epitope of the antigen, wherein said tumor-associated antigen is CA 125, and wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope ~~associated with~~ of the tumor-associated antigen.
118. **(Previously Presented)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex formed from a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.
119. **(Previously Presented)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex formed from a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces cytotoxic T cells reactive with the tumor-associated antigen.
- 120-122. **(Cancelled)**
123. **(Previously Presented)** The method of claim 30, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

124. **(Previously Presented)** The method of claim 104, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.
125. **(Previously Presented)** The method of claim 105, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.
126. **(Previously Presented)** The method of claim 117, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.
127. **(Previously Presented)** The method of claim 118, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.
128. **(Previously Presented)** The method of claim 119, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.
129. **(New)** The method of any of claims 30, 104, 105, 107, 109, 118, and 119, wherein said antibody or antigen binding fragment thereof comprises an Fc portion that binds an Fcγ RII receptor.
130. **(New)** The method of any of claims 30, 104, 105, 107, 109, 118, and 119, wherein said antibody is an IgG1 antibody or an antigen-binding fragment thereof.
131. **(New)** The composition of claim 85 or 117, wherein said antibody or antigen binding fragment thereof comprises an Fc portion that binds an Fcγ RII receptor.
132. **(New)** The composition of claim 85 or 117, wherein said antibody is an IgG1 antibody or an antigen-binding fragment thereof.
133. **(New)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising: administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen,
 wherein the tumor-associated antigen is CA 125, and the first epitope of the tumor-associated antigen is the epitope bound by an antibody produced by the hybridoma having ATCC deposit number PTA-1883, and,
 wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.

134. (New) The composition of claim 85, or 117, wherein the antigen is a human antigen.